Breaking News, Collaborations & Alliances

OPTI-STEM Cell Therapy Consortium Led by CDMO Cell-Easy

Receives €7M from French Govt. and Bpifrance and €800,000 from Occitanie Region to democratize access to cell therapy in France and Europe.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The OPTI-STEM project is one that aims to optimize the production of mesenchymal stem cells (MSCs) in order to democratize access to them and allow the diversification of therapeutic applications of this type of cells and their derivatives, such as exosomes. To achieve this objective, the R&D consortium led by contract development and manufacturing organization (CDMO) Cell-Easy has obtained public funding of more than €7 million as part of the “Biotherapies and Bioproduction of Innovat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters